Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
03 Abril 2024 - 6:05AM
Tevogen Bio Holdings Inc (‘Tevogen Bio’) (Nasdaq: TVGN), a
clinical-stage biotech company, announces the appointment of Tapan
V Shah as Head of Investor Relations and Corporate Development. Mr.
Shah, a Wall Street veteran with over 25 years of experience across
key financial services industry verticals, brings broad leadership
capabilities to Tevogen Bio.
Most recently, Mr. Shah was Director, Relationship Management,
in Citigroup’s Client organization, where he was also a member of
the Executive Office. Prior to Citigroup, he worked in Morgan
Stanley’s asset management business (MSIM) focused on Equity
Strategy and Product Development. Mr. Shah started his
career in the Investment Banking Division of Goldman
Sachs.
In this new position, Mr. Shah will lead communications with all
financial stakeholders including shareholders, lenders, research
analysts, and investment bankers. He will also lead the M&A and
capital raising functions at Tevogen Bio and be responsible for
consolidating and analyzing inputs from key internal stakeholders
to advise the executive leadership team on an appropriate course of
action. Mr. Shah will report directly to Tevogen Bio’s Founder and
Chief Executive Officer, Dr. Ryan Saadi.
Mr. Shah completed a bachelor’s degree in mathematics from New
York University’s Courant Institute of Mathematical Sciences and
certified post-graduate programs at Harvard Business School.
“Mr. Shah's extensive background in financial services, paired
with his ability to forge trusted-advisor relationships, will steer
our company through its upcoming stages of growth and play a
crucial role as we venture into new areas of the healthcare
ecosystem,” remarked Dr. Ryan Saadi.
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company
harnessing one of nature’s most powerful immunological weapons,
CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically
unmodified precision T cell therapies for the treatment of
infectious diseases, cancers, and neurological disorders, aiming to
address the significant unmet needs of large patient populations.
Tevogen Bio’s Leadership believes that sustainability and
commercial success in the current era of healthcare rely on
ensuring patient accessibility through advanced science and
innovative business models. Tevogen Bio has reported positive
safety data from its proof-of-concept clinical trial, and its key
intellectual property assets are wholly owned by the company, not
subject to any third-party licensing agreements. These assets
include three granted patents and twelve pending patents, two of
which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry
leaders and distinguished scientists with drug development and
global product launch experience. Tevogen Bio’s leadership believes
that accessible personalized therapeutics are the next frontier of
medicine, and that disruptive business models are required to
sustain medical innovation.
Contacts
Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available
at:https://www.globenewswire.com/NewsRoom/AttachmentNg/c0c9d97e-d435-41ba-b7b9-940869bd8dd6
Tevogen Bio (NASDAQ:TVGN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Tevogen Bio (NASDAQ:TVGN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024